Integra LifeSciences receives ‘hold’ rating — 4 facts

Zacks analysts upgraded Integra LifeSciences stock from a “sell” rating to a “hold” rating, according to The Market Business.

Advertisement

Here are four facts:

 

1. On Wed., Sept. 30, the company’s stock traded up 0.13 percent, reaching $59.55.

 

2. Integra LifeSciences has a 50-day moving average of $62.16 and a 200-day moving average of $60.28.

 

3. The company’s 52-week low is $42.09 and 52-week high is $68.46.

 

4. Integra LifeSciences has a market cap of $1.97 billion and a P/E ratio of $49.05.

 

More articles on orthopedics:
Drs. James Andrews, Christopher E. Baker & more — 10 orthopedic surgeons to know
Dr. Brian Weatherford joins Illinois Bone & Joint Institute: 4 things to know
Dr. Donald Gajewski joins Mission Health: 4 points

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

Is ambulatory care healthcare’s big margin engine? 4 leaders weigh in

Wednesday, July 29
1:00 PM - 2:00 PM CDT

Presenters: Joe Ganley, athenahealthJeffrey Flynn, CASC, Gramercy Surgery CenterBryan Tsao, Access Center, Loma Linda University HealthJason Zepeda, Northridge Hospital Medical Center, CommonSpirit HealthGreg DeConciliis, PA-C, CASC, Boston Out­Patient Surgical Suites

Advertisement

Next Up in Orthopedic

Advertisement

Comments are closed.